Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Pfizer Inc. is conducting a Phase 3 study titled ‘A Phase 3 Multi-Center, Long-Term Extension Study Investigating the Efficacy and Safety of Abrocitinib, With or Without Topical Medications, Administered to Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis.’ The study aims to evaluate the efficacy and safety of Abrocitinib, an oral medication, in treating moderate to severe atopic dermatitis in patients aged 12 and older. This research is significant as it could offer a new long-term treatment option for those suffering from this chronic skin condition.
The study tests two dosages of Abrocitinib, 100 mg and 200 mg, administered orally once daily. The treatment is designed to alleviate symptoms of atopic dermatitis, potentially improving the quality of life for patients.
This interventional study is randomized with a parallel assignment model and quadruple masking, meaning neither participants nor those administering the treatment know who is receiving the actual drug versus a placebo. The primary purpose of the study is treatment-focused.
The study began on March 8, 2018, with the primary completion date yet to be announced. The last update was submitted on August 11, 2025. These dates are crucial as they indicate the study’s progress and potential timeline for results.
The outcome of this study could significantly impact Pfizer’s stock performance, as a successful result may lead to increased market share in the dermatology sector. Competitors in the pharmaceutical industry will be closely monitoring these developments, as a new effective treatment could shift market dynamics.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.